Brief: EyeGate Pharma To Proceed With PE Pivotal Study
14/07/2020 12:50
July 14 (Reuters) - EyeGate Pharmaceuticals Inc EYEG.O :
* EYEGATE PHARMA TO PROCEED WITH PE PIVOTAL STUDY
* EYEGATE PHARMACEUTICALS INC - ANTICIPATES COMPLETING
TESTING BY
END OF 2020
* EYEGATE PHARMACEUTICALS INC - COMPANY ANTICIPATES
COMPLETING
TESTING BY END OF 2020
Source text for Eikon: ID:nNDL12tpc5
Further company coverage: EYEG.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kiora Pharmaceuticals
See all newsKiora Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kiora Pharmaceuticals, Inc. expected to post a loss of 62 cents a share - Earnings Preview
Brief: Kiora Pharmaceuticals Inc - Enters Securities Purchase Agreement On April 3, 2026 - SEC Filing
Kiora Pharmaceuticals posts 2025 net loss as expenses rise
Brief: Kiora Pharmaceuticals Files For Mixed Shelf Offering Of Up To $100 Million- SEC Filing